Friday, July 10, 2026

pharma · Pulmonary Embolism · Carcinoma, Hepatocellular

Bayer HealthCare Animal

Bayer HealthCare AG is a pharma organization headquartered in EU. Primary therapeutic focus areas include Pulmonary Embolism, Carcinoma, Hepatocellular, Colorectal Neoplasms, Macular Edema, Prevention of Ischemic Stroke.

3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us HQ
1919 Founded
8 Employees
EMA registrant Type
Company details
Status
Public
HQ
3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us
Founded
1919
Employees
8
Programs
34
Drugs
32
Patents
24

Quick answer

Bayer HealthCare AG is a pharma organization headquartered in EU. Primary therapeutic focus areas include Pulmonary Embolism, Carcinoma, Hepatocellular, Colorectal Neoplasms, Macular Edema, Prevention of Ischemic Stroke. NovaPharmaNews links 34 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (25), phase 2 (5), phase 1 (4).

Company snapshot

At Bayer, we know livestock is your livelihood. Learn more about our dedication to strengthening your animal health programs and livestock operations.

  • 34 active pipeline program(s) linked via ClinicalTrials.gov.
  • 24 US patent(s) indexed to this assignee profile.
  • 34 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bayer HealthCare Animal. Not investment advice.

Lead pipeline drugs

Active clinical programs

  • 15161 Macular Edema
    Phase 3
  • 91774 Metrorrhagia
    Phase 3
  • 91781 Primary Dysmenorrhea
    Phase 3
  • 91782 Breast Cancer
    Phase 3

Momentum

Proprietary activity score for Bayer HealthCare Animal.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 35 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for Bayer HealthCare Animal.

  1. Clinical update

    91396 — Phase 2

  2. Clinical update

    91782 — Phase 3

  3. Clinical update

    91774 — Phase 3

  4. Clinical update

    91781 — Phase 3

  5. Clinical update

    15161 — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Bayer HealthCare Animal?

    Bayer HealthCare AG is a pharma organization headquartered in EU. Primary therapeutic focus areas include Pulmonary Embolism, Carcinoma, Hepatocellular, Colorectal Neoplasms, Macular Edema, Prevention of Ischemic Stroke. NovaPharmaNews links 34 clinical program(s), 0 drug profile

  • Is Bayer HealthCare Animal publicly traded?

    Bayer HealthCare Animal appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Bayer HealthCare Animal develop or market?

    We link 32 drug profile(s) where Bayer HealthCare Animal is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bayer-healthcare-ag#company-drugs.

  • What are the latest developments for Bayer HealthCare Animal?

    In the last 12 months our linked public records show 34 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Bayer HealthCare Animal focus on?

    Bayer HealthCare Animal focuses on Pulmonary Embolism, Carcinoma, Hepatocellular, Colorectal Neoplasms based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
36
Oncology
11
Infectious Disease
5
Cardiology
3